MedPath

A randomized double-blind controlled study for the evaluation of the clinical efficacy of the Tibetan medicine 'Fifteen Weisaierdou Pills'

Phase 4
Conditions
cholecystitis
Registration Number
ITMCTR2000003469
Lead Sponsor
Qinghai Jiumei Tibetan Medicine Pharmaceutical Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

(1) Consensus Opinions on Medical Diagnosis and Treatment of Chronic Cholecystitis and Cholecystolithiasis in China (2018) diagnostic criteria of Chronic Cholecystitis;
(2) It meets the diagnostic criteria of Tibetan medicine and is hot, with more than 5 clinical symptoms;
(3) The age range is 20-70 years old;
(4) Those who voluntarily participated in the research and signed the informed consent.

Exclusion Criteria

(1) Exclude patients with acute non-calculous cholecystitis, gallbladder polyps, gallbladder cancer, gastric ulcers, gastric erosion, etc. with severe stomach disease;
(2) Combined with other diseases, such as severe heart, brain, kidney, lung dysfunction and trauma;
(3) Pregnant women and lactating women.
(4) Have not taken other Chinese and Western medicines for treating cholecystitis within 15 days, such as Xiaoyanlidan tablets;
(5) Circumstances that other researchers think are not suitable for participating in the research.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hepatobiliary imaging changes;
Secondary Outcome Measures
NameTimeMethod
Evaluation of curative effect of Tibetan medicine syndrome;Adverse events;
© Copyright 2025. All Rights Reserved by MedPath